Enamine contributes to the discovery of promising broad-spectrum coronavirus antiviral
Enamine, a leading chemistry and R&D services company, today announced that it was a key synthetic chemistry contributor to a first-of-its-kind, open-science approach that led to the development of a promising broad-spectrum coronavirus antiviral pre-clinical candidate. Enamine’s chemistry platform delivered over 2,000 new compounds during the early stages of the programme that resulted in the discovery of pre-clinical candidate ASAP-0017445. The candidate is designed to be a direct-to-generic, globally accessible treatment ready for future coronavirus pandemics.
